Characterization and synthesis of hardystonite (HT) as a novel nanobioceramic powder

Document Type: Research Paper

Authors

Advanced Materials Research Center, Faculty of Materials Engineering, Najafabad Branch, Islamic Azad University, Najafabad, Iran

10.7508/nmj.2016.02.008

Abstract

Objective(s): Hardystonite (HT) has been successfully prepared by a modified sol-gel method. We hypothesized that
nano-sized (HT) would mimic more efficiently the nanocrystal structure and function of natural bone apatite, owing to the higher surface area, compare to conventional micron-size (HT).
Materials and Methods: The hardystonite nanopowder was prepared via a modified sol-gel method.Optimization in calcination temperature and mechanicalball milling resulted in a pure and nano-sized powder which characterized by means of scanning electron microscopy(SEM), X-ray diffraction (XRD), transmission electron microscopy (TEM) and fourier transform infrared Spectroscopy
(FT–IR).
Results: Pure (HT) powders were successfully obtained via a simple sol-gel method followed by calcination at1150 °C. Mechanical grinding in a ceramic ball mill for 6 hours resulted in (HT) nanoparticles in the range of about 32-55nm.
Conclusion: Our study suggested that nanohardystonite (NHT) might be a potential candidate by itself as a nanobioceramic filling powder or in combination with other biomaterials as a composite scaffold in bone tissue regeneration.

Keywords


[1]  Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008; 1252: 12-52.

[2]  Moffat B.A, David A.E. Yu F, Bergemann C, Ross BD, Yang VC. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008; 29: 487-496.

[3]  Kumar CSSR, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapyand controlled drug delivery. Adv Drug Deliv Rev. 2011; 63: 789-808.

[4]  Laurant S, Dutz S, Hafeli U.O, Mahmoudi M. Magnetic fluid hyperthermia: Focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci. 2011; 166: 8- 23.

[5]  Pouponeau P, Leroux JC, Soulez G, Gaboury L, Martel S. Co-encapsulationof magnetic nanoparticles and doxorubicin into iodegradable microcarriers for deep tissue targeting by vascular MRI navigation. Biomaterials. 2011; 32: 3481-3486.

[6]  Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Controlled Release. 2007; 132: 171-183.

[7]  Wacker M, Zensi A, Kufleitner J, Ruff A, Schütz J, Stock- burger T, Marstaller T, Vogel V. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation. Int J Pharm. 2011; 46: 225-232.

[8]  Longley DB, Harkin DP, Johnston P G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev. Cancer, 2003; 3: 330-338.

[9]  Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology J Clin Oncol. 1988; 6: 1653-1664.

[10] Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B Cardiotoxicity of 5- fluorouracil. cardiovasc Hematol Agents Med Chem. 2006; 4(1): 1-5.

[11] Wigmore PM, Mustafa S, El-Beltagy M, Lyons L, Umka J, Bennett G. Effects of 5-FU. Adv Exp Med Biol. 2010; 678: 157-164.

[12] Fadeian G, Shojaosadati SA, Kouchakzadeh H, Shokri F, Soleimani M. Targeted Delivery of 5-fluorouracil with Monoclonal Antibody Modified Bovine Serum Albumin Nanoparticles. Iranian J Pharm Res. 2015; 14(2) 395- 405.

[13] H.Gheisari, E.Karamian , M.Abdellahi , A novel hydroxyapatite–Hardystonite nanocom- positeceramic.  Ceram Int. 2015; 41: 5967–5975

[14] Gheisari H, Karamian E , Preparation and characterization of hydroxyapatite reinforced with hardystonite as a novel bio-nanocomposite for tissue engineering , Nanomed J. 2015; 2(1): 141-152.

[15] N.Y. Iwata, G.H. Lee, Y. Tokuoka, N. Kawashima, Colloids Surf B interfaces. 2004; 34: 239–245.

[16] Karamian E , Abdellahi M, Gheisari H , I, Fluorine-substituted HA reinforced with zircon as a novel nano-biocomposite ceramic: Preparation and characterization. Int. J. Mater. Res. 2015; 106(12): 1258-1290